BPC-157 vs TB-500
Which Healing Peptide Is Right for Your Injury?
BPC-157 and TB-500 are two research peptides that work through different biological pathways to support tissue repair. BPC-157 targets connective tissue — tendons, ligaments, and the gut — while TB-500 focuses on cell migration and blood vessel formation throughout the body. Neither peptide is FDA-approved for human use, both are prohibited by WADA, and the evidence base is primarily animal studies with very limited human data.
Key takeaways
- BPC-157 rebuilds connective tissue (tendons, ligaments, joints) and gut lining through collagen synthesis and fibroblast activation.
- TB-500 supports muscle tears, cardiovascular repair, and large wounds through cell migration and angiogenesis (new blood vessel formation).
- For tendon or ligament injuries, BPC-157 has the stronger mechanistic rationale. For muscle strains and systemic recovery, TB-500 has the edge.
- The “Wolverine Stack” combines both for injuries involving multiple tissue types: BPC-157 rebuilds structure while TB-500 delivers blood flow and repair cells.
- PeptideRx rates the evidence for both BPC-157 and TB-500 as Grade C, reflecting primarily animal and in vitro data with limited human clinical evidence.
Before you start All peptide protocols require a physician evaluation. Both BPC-157 and TB-500 promote angiogenesis (new blood vessel formation), which is a theoretical concern for anyone with active cancer or a recent cancer history — consult an oncologist before considering either peptide in that context.
What is BPC-157?
Body Protection Compound-157 (BPC-157) is a 15-amino-acid synthetic peptide derived from a protective protein found in human gastric juice. It works primarily by stimulating fibroblasts — the cells that build and repair connective tissue — to produce Type I and Type III collagen, the structural proteins behind tendons, ligaments, and joint capsules.
When tissue gets damaged, fibroblasts lay down new collagen to rebuild it. BPC-157 accelerates that process. It also protects and rebuilds the GI mucosa (stomach and intestinal lining), a capability TB-500 does not share.
How BPC-157 heals tissue
BPC-157 works through three main pathways:
Collagen production: BPC-157 activates fibroblasts to produce Type I and Type III collagen. A 2011 study (Chang et al., Journal of Applied Physiology) showed that BPC-157 enhanced tendon outgrowth, cell survival, and cell migration in tendon-healing models.
Angiogenesis: BPC-157 upregulates VEGFR2 (vascular endothelial growth factor receptor 2) and eNOS (endothelial nitric oxide synthase), promoting new blood vessel formation at injury sites.
Gastric mucosal protection: BPC-157 originated from research into stomach lining repair. It protects and rebuilds GI mucosa, making it effective for ulcers, leaky gut, IBD, and inflammatory bowel conditions — and the only peptide in this comparison with a gut-healing application.
Where BPC-157 performs best
BPC-157’s strongest applications cover connective tissue and the gastrointestinal tract:
- Tendon injuries (Achilles, patellar, rotator cuff)
- Ligament tears (ACL, MCL, ankle sprains)
- Joint capsule repair
- Gut conditions (ulcers, leaky gut, IBD, Crohn’s disease)
A 2025 systematic review (Vasireddi et al., HSS Journal, PMID: 40756949) screened 544 articles and confirmed that BPC-157 improved functional, structural, and biomechanical outcomes across tendon, ligament, muscle, and bone injury models in preclinical studies. Only 1 of the 36 included studies involved human subjects.
Evidence grade: PeptideRx rates the evidence for BPC-157 tendon and connective tissue repair as Grade C, reflecting primarily animal model data with limited human clinical evidence.
Administration options
BPC-157 offers three delivery routes — more flexibility than TB-500:
| Route | Dose | Frequency | Best for |
|---|---|---|---|
| Subcutaneous injection | 250–500 mcg | Once daily | Systemic healing, general recovery |
| Intramuscular injection | 500 mcg | Once daily | Targeted repair near injury site |
| Oral capsule | 250–500 mcg | 1–2 times daily | GI conditions only |
Oral delivery works for gut conditions because BPC-157 is unusually stable in gastric acid. For musculoskeletal injuries, injectable protocols are preferred. No loading phase is required.
Onset: Most practitioners report initial improvements — reduced pain, better mobility — within 7–14 days of consistent dosing. Gut healing may show early effects within days.
Learn more about BPC-157’s mechanisms and research evidence in our full BPC-157 profile.
What is TB-500?
TB-500 is a synthetic peptide fragment corresponding to amino acids 17–23 of Thymosin Beta-4, a naturally occurring 43-amino-acid protein found in virtually every human cell. The fragment is typically sold in acetylated form (Ac-LKKTETQ) for improved stability.
Where BPC-157 builds structure, TB-500 moves repair cells and grows the blood supply to feed the healing process. These are fundamentally different jobs.
How TB-500 heals tissue
TB-500 operates through two primary pathways:
Cell migration: Thymosin Beta-4’s actin-binding domain reorganizes the internal cellular skeleton (actin cytoskeleton), enabling repair cells to travel to injury sites faster and more efficiently. Philp et al. (2003, FASEB Journal, PMID: 14500546) demonstrated that this 7-amino-acid actin-binding motif is directly responsible for its angiogenic and cell migration activity.
Angiogenesis: TB-500 promotes new blood vessel formation through VEGF (vascular endothelial growth factor) signaling pathways and integrin-linked kinase (ILK) activation. Bock-Marquette et al. (2004, Nature) showed that Thymosin Beta-4 activates ILK, supporting cardiac cell migration, survival, and repair.
Wound healing: Malinda et al. (1999, Journal of Investigative Dermatology, PMID: 10469335) reported a 42% increase in wound re-epithelialization (surface skin cell regrowth) at day 4 and up to 61% at day 7 in preclinical wound models.
Where TB-500 performs best
TB-500’s systemic action makes it the better choice for:
- Muscle strains and tears (satellite cell migration to damaged muscle fibers for regeneration)
- Cardiovascular tissue repair (post-ischemic cardiac models show significant benefit)
- Large or chronic wounds (preclinical re-epithelialization data, Malinda et al., 1999)
- Systemic recovery from multi-area injuries
TB-500 has no gut-healing application. For GI conditions, BPC-157 is the only relevant option here.
Evidence grade: PeptideRx rates the evidence for TB-500 muscle and systemic repair as Grade C, reflecting primarily animal and in vitro data with limited human clinical evidence.
Administration
TB-500 is subcutaneous injection only — no oral option exists, as the peptide does not survive gastric digestion. A loading phase is required to build tissue saturation.
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Loading | 2–5 mg | 2–3 times/week | Weeks 1–2 |
| Maintenance | 2–5 mg | 1–2 times/week | Weeks 3–6+ |
Systemic improvements typically appear within 1–3 weeks. Muscle recovery becomes noticeable within 7–14 days in many cases.
Learn more about TB-500’s cardiovascular and wound-healing research in our full TB-500 profile.
BPC-157 vs TB-500: How they compare
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Full name | Body Protection Compound-157 | Thymosin Beta-4 fragment (amino acids 17–23) |
| Amino acids | 15 | 7 (acetylated fragment of 43-AA parent protein) |
| Primary mechanism | Collagen I/III synthesis; fibroblast activation | Cell migration; angiogenesis |
| Tissue focus | Tendons, ligaments, joints, GI tract | Muscle, cardiovascular tissue, systemic wounds |
| Administration | SubQ injection, IM injection, oral capsule | SubQ injection only (loading phase required) |
| Typical dose | 250–500 mcg daily | 2–5 mg, 2–3×/week loading; then 1–2×/week |
| Onset | 7–14 days for targeted injuries; days for gut | 1–3 weeks for systemic improvement |
| Best for | Tendonitis, ligament tears, joint pain, gut healing | Muscle tears, cardiac repair, large wounds, systemic recovery |
| FDA status | Not approved; Category 2 (reclassification pending) | Not approved; Category 2 (reclassification pending) |
| WADA status | Prohibited: S0 (Non-Approved Substances) | Prohibited: S2.3 (Growth Factors) |
| Evidence grade | Grade C | Grade C |
The core distinction: BPC-157 builds structure. TB-500 delivers the building crew and supplies. BPC-157 signals fibroblasts to produce collagen at the injury site. TB-500 moves repair cells toward the damage and grows new blood vessels to feed the healing process. These are fundamentally different jobs — which is why they work well together.
Learn more about how these peptides compare to other healing compounds.
Which peptide is right for your injury?
Your injury type is the deciding factor. The table below maps common injuries to the peptide with the stronger mechanistic rationale.
| Injury type | Recommended peptide | Why |
|---|---|---|
| Tendonitis (Achilles, patellar, rotator cuff) | BPC-157 | Collagen I synthesis directly rebuilds damaged tendon matrix |
| Ligament tears (ACL, MCL, ankle sprains) | BPC-157 | Collagen I/III production restores ligament structural integrity |
| Muscle strains and tears | TB-500 | Cell migration brings satellite cells to damaged muscle fibers for regeneration |
| Gut conditions (ulcers, leaky gut, IBD) | BPC-157 only | Gastric mucosal healing; TB-500 has no GI application |
| Cardiovascular tissue repair | TB-500 | Angiogenesis improves cardiac perfusion and supports cardiomyocyte survival |
| Large or chronic wounds | TB-500 | Enhanced re-epithelialization, collagen deposition, and blood vessel formation |
| Multi-tissue or chronic injuries | Stack both | Complementary pathways: structural repair + systemic healing capacity |
| Post-surgical recovery (multiple tissue types) | Stack both | BPC-157 targets the surgical site; TB-500 supports systemic recovery |
When to use just one peptide
Single-peptide protocols work well for isolated injuries with a clear tissue type. A patellar tendon strain responds to BPC-157 alone — collagen synthesis targets the specific tissue. A hamstring tear responds to TB-500 alone — cell migration brings muscle repair cells to the tear site. Leaky gut or IBS requires BPC-157 only, with oral delivery; TB-500 offers nothing here.
When to stack both
Consider combining both peptides when the injury involves both connective tissue and muscle damage — a knee injury affecting both the ACL and surrounding muscle, for example. Post-surgical recovery requiring structural repair and systemic healing is another indication. Single-peptide protocols that have not produced results after 4–6 weeks are also a reasonable trigger for stacking.
Learn more about how to structure a combined peptide cycle for your injury type.
The Wolverine Stack: BPC-157 + TB-500 combined
Key takeaways
- BPC-157 rebuilds the structural matrix (collagen, connective tissue); TB-500 mobilizes repair cells and grows the blood vessels that feed the rebuilding process.
- The two peptides use different, non-overlapping pathways — combination is logically sound for multi-tissue injuries.
- Standard cycle: 4–6 weeks on, followed by a 2–4 week break to assess results.
- Neither peptide requires dose reduction when stacking; full doses of both are maintained throughout the cycle.
The Wolverine Stack addresses healing from two angles at once. BPC-157 creates the local structural repair environment. TB-500 moves the right cells into that environment and ensures they have the circulation to work.
Why the combination works
The two peptides use different, non-competing pathways:
BPC-157 activates fibroblasts at the injury site, stimulates collagen I/III production, and upregulates VEGFR2/eNOS for local angiogenesis.
TB-500 reorganizes actin cytoskeletons to accelerate cell migration, activates ILK for cell survival signaling, and promotes VEGF-mediated blood vessel formation systemically.
The result: BPC-157 lays the structural groundwork at the injury site. TB-500 ensures the repair workforce arrives — and has the blood supply to operate.
Wolverine Stack protocol
| Week | BPC-157 protocol | TB-500 protocol | What to expect |
|---|---|---|---|
| 1–2 | 250–500 mcg daily (SubQ or IM near injury) | Loading: 2–5 mg, 3×/week | TB-500 tissue saturation builds; BPC-157 collagen onset begins |
| 3–4 | 250–500 mcg daily (continue) | 2–5 mg, 2×/week | Systemic angiogenesis and structural repair working simultaneously |
| 5–6 | 250–500 mcg daily (continue) | Maintenance: 2–5 mg, 1–2×/week | Measurable injury improvements; functional testing appropriate |
| 7+ | Break: 2–4 weeks | Break: 2–4 weeks | Assess results; plan next cycle if additional healing is needed |
No dose reduction is required for either peptide when stacking. Maintain the full dose of each throughout the cycle.
Chronic tendinopathy or complex post-surgical recovery may extend to 8–12 weeks under physician supervision. Medical supervision is strongly recommended for any multi-peptide protocol.
Learn more about structuring multi-peptide recovery cycles and assessing healing progress.
Dosing and administration
BPC-157 dosing
BPC-157 offers three delivery routes:
| Route | Dose | Technique | Notes |
|---|---|---|---|
| Subcutaneous injection | 250–500 mcg once daily | 29–31 gauge insulin syringe; abdominal fat or upper outer thigh at 45° angle | Best for systemic recovery and general healing |
| Intramuscular injection | 500 mcg once daily | 27–30 gauge needle; within 2–3 inches of injury site | Do NOT inject directly into the tendon |
| Oral capsule | 250–500 mcg, 1–2×/daily | Empty stomach | Effective for GI conditions only; not a substitute for injectable protocols in musculoskeletal injuries |
No loading phase is required for BPC-157.
TB-500 dosing
TB-500 is subcutaneous injection only:
| Phase | Dose | Frequency | Example schedule |
|---|---|---|---|
| Loading (weeks 1–2) | 2–5 mg | 2–3 times/week | Monday / Wednesday / Friday |
| Maintenance (weeks 3–6+) | 2–5 mg | 1–2 times/week | Monday / Thursday |
Use a 27–30 gauge insulin syringe. Inject subcutaneously into the abdominal area. Rotate injection sites across sessions.
Shared preparation requirements
Both peptides ship as lyophilized (freeze-dried) powder and require reconstitution with bacteriostatic water before injection. Reconstituted vials must be refrigerated at 36–46°F and used within 2–4 weeks. Swirl gently during reconstitution — never shake. Discard any vial showing visible particulate matter or unusual color.
Learn more about peptide reconstitution procedure and injection technique.
Side effects and safety
Key takeaways
- Both BPC-157 and TB-500 show favorable safety profiles in available preclinical data and practitioner-reported use.
- Serious adverse events have not been reported in published human studies for either peptide.
- A 2025 safety pilot (Lee & Burgess, Alternative Therapies in Health and Medicine, PMID: 40131143) administered BPC-157 intravenously at 10–20 mg in 2 healthy adults with no adverse effects on cardiac, hepatic, renal, or metabolic markers.
- Both peptides promote angiogenesis — a theoretical concern for individuals with active cancer or recent cancer history.
Documented side effects
| Side effect | Which peptide | Notes |
|---|---|---|
| Injection site redness, swelling, or irritation | Both | Generally resolves within 24–48 hours |
| Headache | Both | Occasional and typically transient |
| Nausea | BPC-157 (especially oral route) | Mild and dose-related |
| Fatigue | Both | Reported by some users during the first few days |
Preclinical safety studies for BPC-157 show no mutagenic, genotoxic, or teratogenic effects at tested doses (Vasireddi et al., 2025, PMID: 40756949).
Contraindications
Both peptides should be avoided in the following situations:
| Contraindication | Reason |
|---|---|
| Active cancer or recent cancer history | Both peptides promote angiogenesis, which could theoretically supply blood to tumors |
| Pregnancy and breastfeeding | Insufficient human safety data for both peptides |
| Bleeding disorders | Altered clotting pathways are a theoretical concern |
| Within 2 weeks of scheduled surgery | Discuss discontinuation timeline with your surgeon |
Learn more about peptide safety monitoring and what to discuss with your physician before starting.
Legal status (2026)
Important: Neither BPC-157 nor TB-500 is FDA-approved for any human therapeutic use. Both remain research compounds as of April 2026.
FDA regulatory status
Both BPC-157 and TB-500 were classified as Category 2 bulk drug substances by the FDA in late 2023. That classification restricts compounding pharmacies from preparing them for patients.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 Category 2 peptides — with both BPC-157 and TB-500 expected to be included — would return to Category 1 status. As of March 2026, the FDA has not published the formal updated list. Category 1 status, if formalized, would allow licensed 503A and 503B compounding pharmacies to prepare these peptides under valid physician prescriptions. Category 1 is not the same as FDA approval.
WADA prohibited status
| Peptide | WADA category | Consequence |
|---|---|---|
| BPC-157 | S0 — Non-Approved Substances | 2–4 year competition ban on positive test |
| TB-500 | S2.3 — Growth Factors and Growth Factor Modulators | 2–4 year competition ban on positive test |
Detection is possible via LC-MS/MS (liquid chromatography-mass spectrometry) testing. Detection windows can extend weeks to months after the last dose. If you are subject to any sports drug testing program — WADA, USADA, NCAA, or any sport-specific organization — do not use either peptide.
Cost comparison
Pricing varies by vendor, vial size, and sourcing:
| Peptide | Typical price per 5 mg vial | Estimated cycle cost |
|---|---|---|
| BPC-157 | $40–$80 | ~$120–$240 for a 4-week cycle at 500 mcg/day (≈14 mg total, 3 vials) |
| TB-500 | $50–$100 | ~$300–$1,200 for a 6-week cycle (30–60 mg total, 6–12 vials) |
| Wolverine Stack (both) | — | ~$400–$1,400 combined depending on dose and duration |
Both peptides have been harder to source through licensed compounding pharmacies since their 2023 Category 2 designation. Quality control from non-pharmacy sources varies significantly. If Category 1 reclassification is finalized, pharmaceutical-grade sourcing from licensed pharmacies will offer substantially better quality assurance than what is currently available.
Learn more about the current FDA regulatory status of compounded peptides and what reclassification means.
The bottom line
BPC-157 and TB-500 heal tissue through different pathways, and the right choice depends on what you are trying to fix. If your injury is a tendon, ligament, joint problem, or a gut condition, BPC-157’s collagen synthesis pathway is the better mechanistic fit. If you are dealing with a muscle tear, a cardiovascular issue, or a large wound requiring systemic healing, TB-500’s cell migration and angiogenesis pathways have the edge. For injuries involving multiple tissue types — or chronic injuries that have not responded to a single peptide — combining both in the Wolverine Stack addresses the problem from two angles at once. Both are research compounds with primarily preclinical evidence, neither is currently available through licensed compounding pharmacies pending formal FDA reclassification, and both are prohibited by WADA. Talk with a licensed physician experienced in peptide protocols before starting either.
Frequently asked questions
What does the research actually show for BPC-157 and TB-500?
Preclinical evidence is strong for both peptides, but human data is limited. BPC-157’s collagen synthesis and tendon-healing effects are documented across multiple animal model studies (Sikiric et al., 1993–2024; Vasireddi et al. systematic review, 2025, PMID: 40756949). Thymosin Beta-4 — TB-500’s parent protein — has well-documented angiogenic and cell migration effects (Philp et al., 2003, PMID: 14500546; Bock-Marquette et al., 2004; Malinda et al., 1999, PMID: 10469335). BPC-157 has 3 published human studies with fewer than 30 total subjects; Thymosin Beta-4 has reached Phase 2 clinical trials for chronic wound healing. Neither has completed large-scale randomized controlled trials.
Are there dangerous interactions or contraindications?
Yes — avoid both peptides with active cancer, pregnancy, breastfeeding, or bleeding disorders. Stop both at least 2 weeks before any scheduled surgery and discuss timing with your surgeon. No drug interactions are formally documented, but inform your physician of all medications and supplements before starting either peptide.
Why is BPC-157 harder to find than TB-500?
Both were placed on the FDA’s Category 2 list in 2023, restricting compounding pharmacy access equally. BPC-157 faced more supply disruption in practice because it was the most widely used peptide on the restricted list and attracted greater enforcement attention. Both remain available through research chemical vendors, but quality varies significantly. Compounding access may return for both if Category 1 reclassification is formally published.
How long should I run a Wolverine Stack cycle?
The standard cycle is 4–6 weeks of combined BPC-157 (daily) plus TB-500 (loading then maintenance), followed by a 2–4 week break. Use the break to assess whether improvements are structural and lasting, or primarily symptomatic. Chronic or post-surgical injuries may extend to 8–12 weeks under physician supervision. Avoid continuous year-round use without medical guidance.
Can I inject BPC-157 directly into an injured tendon?
No. Injecting directly into the tendon risks tendon weakening or structural damage. Inject subcutaneously near the injury site — within 2–3 inches of the affected tendon or ligament. This localized approach increases local peptide concentration while avoiding direct tendon contact. TB-500 does not offer a localized injection option and is typically injected into abdominal fat for systemic distribution.
Will BPC-157 or TB-500 show up on drug tests?
Yes — both peptides are detectable via LC-MS/MS testing and appear on the WADA Prohibited List. BPC-157 falls under S0 (Non-Approved Substances); TB-500 under S2.3 (Growth Factors and Growth Factor Modulators). Detection windows can extend weeks to months after the last dose. A positive test results in a 2–4 year competition ban. Do not use either peptide if you are subject to WADA, USADA, NCAA, or any other sports drug testing program.
Is the Wolverine Stack safe?
No serious adverse events have been reported in published human studies for either peptide individually. Stacking adds complexity: two peptides with overlapping angiogenic mechanisms, and no published human data on their combined use. Medical supervision is required for any multi-peptide protocol. Anyone with a personal or family history of cancer should consult an oncologist before using either peptide, since both promote angiogenesis.
Considering peptide therapy for an injury? Speak with a licensed physician who can review your case and discuss whether BPC-157, TB-500, or a combined protocol is appropriate for your situation.
References
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. doi: 10.1177/15563316251355551. PMID: 40756949
- Philp D, Nguyen M, Scheremeta B, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(15):2109-2111. PMID: 14500546
- Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PMID: 10469335
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780
- Lee E, Burgess K. Safety of intravenous infusion of BPC-157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20-24. PMID: 40131143
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: pleiotropic beneficial activity and its possible relations with neurotransmitter activity. Pharmaceuticals (Basel). 2024;17(4):461. PMC: 11053547
- Smart N, Risebro CA, Melville AAD, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182
- FDA. Certain bulk drug substances for use in compounding may present significant safety risks. FDA.gov. Updated 2024
- WADA. 2025 World Anti-Doping Code International Standard Prohibited List. WADA. 2024
Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Neither BPC-157 nor TB-500 is FDA-approved for any human therapeutic use. Both are classified as research compounds. Dosing protocols described in this guide reflect preclinical research (primarily animal models) and practitioner-reported clinical experience. They are not prescribing recommendations.
Both BPC-157 and TB-500 are prohibited by the World Anti-Doping Agency (WADA). Athletes subject to drug testing should not use either peptide.
Always consult a licensed physician before starting any peptide therapy. PeptideRx does not sell peptides or provide medical consultations. Content is reviewed by a licensed medical professional. For the most current FDA regulatory status, visit FDA.gov. For the current WADA Prohibited List, visit WADA-AMA.org.